Review Article
Efficacy of Nucleot(s)ide Analogs Therapy in Patients with Unresectable HBV-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
Table 1
Characteristics of the included studies.
| | Study | Nature of study | Number of patients (T/C) | Male/female | Age (T/C) | Unresectable treatment | Antiviral therapy | Follow-up (months) | Outcomes |
| | Toyoda et al. 2012 | Retrospective cohort | 81 (21/60) | 67/14 | 60.3/60.6 | TACE | LAM, ETV, ADV | 19.3 | OS, PFS | | Yoshida et al. 2008 | Retrospective cohort | 104 (33/71) | 78/26 | 57/59 | RFA | LAM | NA | OS, RFS | | Zhu et al. 2015 | Retrospective cohort | 176 (58/118) | 152/24 | 48.7/49.8 | TACE | LAM, ADV | NA | OS, PFS | | Xu et al. 2014 | RCT | 181 (92/89) | 164/17 | 56.0/55.1 | TACE | LAM | 24 | OS, PFS | | Sohn et al. 2016 | Retrospective cohort | 228 (125/103) | 170/58 | 55.0/55.2 | RFA | LAM, ETV, CLV, ADV, TDF | 96 | OS | | Zhou et al. 2015 | Retrospective cohort | 224 (80/144) | 209/15 | 48.0/50.5 | TACE | LAM, ADV, ETV | 9.9 | OS |
|
|
RCT: randomized controlled trials; TACE: transarterial chemoembolization; RFA: radiofrequency ablation; OS: overall survival; PFS: progression-free survival; RFS: recurrence-free survival rate.
|
